Amphastar Q3 net revenues up 34% YoY to $112.2M; GAAP EPS $0.59 vs $0.08

Amphastar Pharmaceuticals, Inc.

2021-Q3 EPS reported $0.85 revenue$316,881,000

Net revenues $112.2M (Q3 2021), up 34% from $83.4M in Q3 2020.
GAAP net income $29.5M ($0.59 diluted EPS) vs $3.9M ($0.08) a year ago.
Adjusted non-GAAP net income $23.0M ($0.46 EPS) vs $7.6M ($0.15).
Growth driven by glucagon, Primatene Mist, epinephrine; CEO expects pipeline approvals in 2022.
Nine-month net revenues $316.9M, up 25% YoY; GAAP net income $42.4M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.